Cellectis S.A. (CLLS) Social Stream
CELLECTIS SA (CLLS) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering CLLS.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Current Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2021-11-06 | 6 | $33 | $10 | $21.666 | $3.05 | 610.36% |
| 2021-12-22 | 6 | $33 | $10 | $21.25 | $3.05 | 596.72% |
| 2022-03-11 | 7 | $33 | $10 | $20.2 | $3.05 | 562.3% |
| 2022-05-16 | 6 | $33 | $7 | $18 | $3.05 | 490.16% |
| 2022-05-18 | 6 | $33 | $7 | $18 | $3.05 | 490.16% |
| 2022-05-24 | 7 | $33 | $2 | $15.714 | $3.05 | 415.21% |
| 2022-08-09 | 7 | $33 | $2 | $15 | $3.05 | 391.8% |
| 2022-09-23 | 7 | $36 | $2 | $17.625 | $3.05 | 477.87% |
| 2022-11-04 | 7 | $36 | $2 | $17.25 | $3.05 | 465.57% |
| 2022-11-08 | 7 | $36 | $2 | $15.125 | $3.05 | 395.9% |
| 2022-12-14 | 5 | $24 | $2 | $12.166 | $3.05 | 298.89% |
| 2023-03-10 | 4 | $24 | $2 | $11 | $3.05 | 260.66% |
| 2023-03-13 | 5 | $24 | $2 | $9.857 | $3.05 | 223.18% |
| 2023-05-05 | 6 | $16 | $2 | $8.714 | $3.05 | 185.7% |
| 2023-05-12 | 4 | $16 | $6 | $10 | $3.05 | 227.87% |
| 2023-11-08 | 4 | $16 | $5 | $9.5 | $3.05 | 211.48% |
| 2023-11-22 | 5 | $11 | $5 | $8 | $3.05 | 162.3% |
| 2023-11-29 | 6 | $11 | $3 | $7.5 | $3.05 | 145.9% |
The Trend in the Analyst Price Target
Over the past 43 months, CLLS's average price target has gone down $28.28.
CLLS reports an average of 371.53% for its upside potential over the past 38 weeks.
| Date | Number of Analysts | Highest Target Price | Lowest Target Price | Average Target Price | Share Price | Upside Potential |
|---|---|---|---|---|---|---|
| 2023-04-05 | 6 | 16 | 2 | 8.714 | 1.98 | 340.1% |
| 2023-05-12 | 5 | 16 | 2 | 8.400 | 1.74 | 382.76% |
| 2023-05-12 | 5 | 16 | 6 | 10.000 | 1.74 | 474.71% |
| 2023-05-12 | 6 | 16 | 2 | 8.400 | 1.74 | 382.76% |
| 2023-08-07 | 4 | 16 | 5 | 9.500 | 1.85 | 413.51% |
CLLS Broker Recommendations Summary
| Average Broker Rating | Strong Buy | Buy | Hold | Sell | Strong Sell | Analysts Issuing Recs |
|---|---|---|---|---|---|---|
| 1.33 | 5 | 0 | 1 | 0 | 0 | 6 |
The Trend in the Broker Recommendations
Over the past 35 weeks, CLLS's average broker recommendation rating improved by 0.8.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- CLLS has a lower variance in analysts' estimates than -2830.16% of all US stocks.
- To contextualize these metrics, consider that out of all US stocks, CELLECTIS SA's upside potential (average analyst target price relative to current price) is higher than 2808.65% of them.
- To contextualize these metrics, consider that out of Healthcare stocks, CELLECTIS SA's average analyst price target is greater than 728.65% of them.
- In terms of how CELLECTIS SA fares relative to stocks in the small market cap category, note that its number of analysts covering the stock is higher than 2045.04% of that group.
Stocks similar to CELLECTIS SA in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ADAP, VYGR, and ATRA.
View All Top Stocks by Price Target
Is CLLS a Buy, Hold or Sell? See the POWR Ratings now!